[go: up one dir, main page]

WO2008078726A1 - 固形製剤 - Google Patents

固形製剤 Download PDF

Info

Publication number
WO2008078726A1
WO2008078726A1 PCT/JP2007/074781 JP2007074781W WO2008078726A1 WO 2008078726 A1 WO2008078726 A1 WO 2008078726A1 JP 2007074781 W JP2007074781 W JP 2007074781W WO 2008078726 A1 WO2008078726 A1 WO 2008078726A1
Authority
WO
WIPO (PCT)
Prior art keywords
solid preparation
azelnidipine
olmesartan medoxomil
disclosed
contact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074781
Other languages
English (en)
French (fr)
Inventor
Takeshi Hamaura
Ikumasa Ohono
Ryoichi Hayakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2008551104A priority Critical patent/JP5241510B2/ja
Publication of WO2008078726A1 publication Critical patent/WO2008078726A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

オルメサルタンメドキソミルとアゼルニジピンを含有する安定な固形製剤を提供する。 オルメサルタンメドキソミルとアゼルニジピンを互いに接触しないように分離配合した固形製剤。
PCT/JP2007/074781 2006-12-26 2007-12-25 固形製剤 Ceased WO2008078726A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551104A JP5241510B2 (ja) 2006-12-26 2007-12-25 固形製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006349475 2006-12-26
JP2006-349475 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078726A1 true WO2008078726A1 (ja) 2008-07-03

Family

ID=39562515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074781 Ceased WO2008078726A1 (ja) 2006-12-26 2007-12-25 固形製剤

Country Status (4)

Country Link
JP (1) JP5241510B2 (ja)
KR (1) KR20090094288A (ja)
TW (1) TWI402083B (ja)
WO (1) WO2008078726A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
JP2011225537A (ja) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd 固形製剤の製造方法
JP2012532118A (ja) * 2009-06-30 2012-12-13 サノフイ イルベサルタンおよびアムロジピンを含む固体医薬固定用量組成物、これらの調製ならびにこれらの治療用途
JP2013023452A (ja) * 2011-07-15 2013-02-04 Nipro Corp カルシウムブロッカーを含有する固形医薬組成物
CN103239418A (zh) * 2013-05-29 2013-08-14 南京正大天晴制药有限公司 一种阿折地平片剂及其制备方法
JP2017071561A (ja) * 2015-10-05 2017-04-13 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
JP2006298764A (ja) * 2005-04-15 2006-11-02 Sankyo Co Ltd 高血圧症治療に有用な複合体
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
JP2006298764A (ja) * 2005-04-15 2006-11-02 Sankyo Co Ltd 高血圧症治療に有用な複合体
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUMOTO M.: "Yakuzaigaku Manual", vol. 1ST ED., 1989, NANZANDO CO., LTD., pages: 114 *
OKANO T.: "Shin.Yakuzaigaku Soron", vol. 3RD ED., 1987, NANKODO CO., LTD. HAKKO, pages: 134 - 145 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
JPWO2010107081A1 (ja) * 2009-03-19 2012-09-20 第一三共株式会社 包装により安定保存された固形製剤
JP2014139256A (ja) * 2009-03-19 2014-07-31 Daiichi Sankyo Co Ltd 包装により安定保存された固形製剤
JP2012532118A (ja) * 2009-06-30 2012-12-13 サノフイ イルベサルタンおよびアムロジピンを含む固体医薬固定用量組成物、これらの調製ならびにこれらの治療用途
JP2011225537A (ja) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd 固形製剤の製造方法
JP2013023452A (ja) * 2011-07-15 2013-02-04 Nipro Corp カルシウムブロッカーを含有する固形医薬組成物
CN103239418A (zh) * 2013-05-29 2013-08-14 南京正大天晴制药有限公司 一种阿折地平片剂及其制备方法
CN103239418B (zh) * 2013-05-29 2014-09-03 南京正大天晴制药有限公司 一种阿折地平片剂及其制备方法
JP2017071561A (ja) * 2015-10-05 2017-04-13 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
WO2017061426A1 (ja) * 2015-10-05 2017-04-13 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
US10632074B2 (en) 2015-10-05 2020-04-28 Daido Chemical Corporation Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product

Also Published As

Publication number Publication date
TWI402083B (zh) 2013-07-21
TW200835526A (en) 2008-09-01
JPWO2008078726A1 (ja) 2010-04-30
KR20090094288A (ko) 2009-09-04
JP5241510B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
EP1999811B8 (en) Fuel cells
GB2434691B8 (en) Fuel cell.
EP2061948B8 (en) Capillary injector
WO2008078726A1 (ja) 固形製剤
EP2274131A4 (en) Diffusion bonding
ZA200901212B (en) Improvements of the biovailability of active substances having an amidine function in medicaments
WO2008078729A1 (ja) 溶出性改善方法
AU2006901034A0 (en) Improvements in piles
WO2011066484A9 (en) Isoxazoline compounds in type 2 diabetes and other maladies
AU2006900573A0 (en) Improvements in seating
AU2006902635A0 (en) Improvements in engine utilization
AU2006906313A0 (en) Improvements in coffee production.
AU2006902300A0 (en) Improvements in footwear
AU2006903771A0 (en) Improvements in Spacer Type Materials
AU2007306595B2 (en) Authenticity feature in the form of luminescent substances
AU2007901638A0 (en) Oxygen injector
AU2006902899A0 (en) Changed cells
HK1127087A (en) Hemangio-colony forming cells
AU2007904137A0 (en) Gaming machine with two-stage feature determination
AU2007101262A4 (en) Improvements in cots
AU3442P (en) With Love Lavandula hybrid
AU2007902603A0 (en) Improvements in engine utilization
GB0619078D0 (en) Improvements in pizza preparation
AU2006901394A0 (en) Electrochemical sensor
WO2009073173A9 (en) Anti-malpractice in seu

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860010

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551104

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097012661

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860010

Country of ref document: EP

Kind code of ref document: A1